Published in J Clin Oncol on November 13, 2006
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene (2007) 3.17
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol (2011) 3.02
Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst (2008) 2.24
Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys (2011) 1.74
HER2: biology, detection, and clinical implications. Arch Pathol Lab Med (2011) 1.68
Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res (2011) 1.39
Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods. Cancer Manag Res (2014) 1.35
Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int (2014) 1.21
Ultrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model. J Control Release (2012) 1.18
Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol (2014) 1.16
The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma. PLoS One (2011) 1.14
Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. Cancer Treat Rev (2012) 1.06
Blood-brain barrier integrity and breast cancer metastasis to the brain. Patholog Res Int (2010) 1.05
Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease. Curr Opin Obstet Gynecol (2011) 1.03
Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer. Int J Clin Oncol (2009) 1.03
Leptomeningeal metastases in breast cancer. Am J Cancer Res (2013) 1.00
Breast cancer brain metastases: the last frontier. Exp Hematol Oncol (2015) 0.99
New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer. Nat Clin Pract Oncol (2008) 0.99
Translational research in brain metastasis is identifying molecular pathways that may lead to the development of new therapeutic strategies. Eur J Cancer (2010) 0.98
Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. Br J Cancer (2014) 0.94
Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat (2012) 0.94
Molecular subtype classification is a determinant of non-sentinel lymph node metastasis in breast cancer patients with positive sentinel lymph nodes. PLoS One (2012) 0.92
Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy. J Korean Med Sci (2009) 0.90
Prognostic factors and survival of patients with brain metastasis from breast cancer who underwent craniotomy. Cancer Med (2015) 0.90
Targeted therapy in her2-positive metastatic breast cancer: a review of the literature. Curr Oncol (2015) 0.89
Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen. Breast Cancer Res Treat (2012) 0.89
A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity. Breast Cancer Res (2014) 0.86
Relationship between HER-2 overexpression and brain metastasis in esophageal cancer patients. World J Gastrointest Oncol (2012) 0.86
Molecular interactions in the development of brain metastases. Int J Mol Sci (2013) 0.85
Brain metastases research 1990-2010: pattern of citation and systematic review of highly cited articles. ScientificWorldJournal (2012) 0.85
Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo. Oncoimmunology (2012) 0.84
Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death. BMC Cancer (2011) 0.83
Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy. Oncologist (2012) 0.83
Structure-based Design of Peptides with High Affinity and Specificity to HER2 Positive Tumors. Theranostics (2015) 0.81
Gamma knife radiosurgery for brain metastases from breast cancer. J Korean Neurosurg Soc (2013) 0.81
Blood-brain barrier remodeling during brain metastasis formation. Mol Med (2016) 0.80
Breaking and entering into the CNS: clues from solid tumor and nonmalignant models with relevance to hematopoietic malignancies. Clin Exp Metastasis (2013) 0.80
T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. Clin Exp Metastasis (2014) 0.78
Clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer. Cancer Biol Ther (2012) 0.78
Molecular and Genetic Predictors of Breast-to-Brain Metastasis: Review and Case Presentation. Cureus (2015) 0.77
HER2-positive, trastuzumab-resistant metastatic esophageal cancer presenting with brain metastasis after durable response to dual HER2 blockade: a case report. J Gastrointest Oncol (2014) 0.76
CNS metastases of breast cancer show discordant immunohistochemical phenotype compared to primary. J Cancer Res Clin Oncol (2012) 0.76
Receptor change-clinicopathologic analysis of matched pairs of primary and cerebral metastatic breast cancer. J Cancer Res Clin Oncol (2013) 0.76
HER2 Targeting Peptides Screening and Applications in Tumor Imaging and Drug Delivery. Theranostics (2016) 0.76
HER2-Orientated Therapy in Early and Metastatic Breast Cancer. Breast Care (Basel) (2016) 0.75
Is prophylactic cranial irradiation a possible option for human epidermal growth factor receptor 2-positive breast cancer? J Clin Oncol (2007) 0.75
NatHER: protocol for systematic evaluation of trends in survival among patients with HER2-positive advanced breast cancer. Syst Rev (2015) 0.75
The combinatorial approach of laser-captured microdissection and reverse transcription quantitative polymerase chain reaction accurately determines HER2 status in breast cancer. Biomark Res (2016) 0.75
Nearly Complete Response of Brain Metastases from HER2 Overexpressing Breast Cancer with Lapatinib and Capecitabine after Whole Brain Irradiation. Case Rep Oncol Med (2013) 0.75
Have changes in systemic treatment improved survival in patients with breast cancer metastatic to the brain? J Oncol (2008) 0.75
Pattern of Local Recurrence and Distant Metastasis in Breast Cancer By Molecular Subtype. Cureus (2016) 0.75
Subtype is a predictive factor of nonsentinel lymph node involvement in sentinel node-positive breast cancer patients. J Breast Cancer (2014) 0.75
Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma. Neuro Oncol (2017) 0.75
Methods and results of local treatment of brain metastases in patients with breast cancer. Contemp Oncol (Pozn) (2017) 0.75
Radiotherapy of brain metastases from breast cancer: Treatment results and prognostic factors. Oncol Lett (2016) 0.75
New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes. PLoS One (2017) 0.75
Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis. Breast Cancer Res Treat (2017) 0.75
Adjuvant docetaxel for node-positive breast cancer. N Engl J Med (2005) 8.00
Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. CMAJ (2006) 4.79
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol (2009) 4.66
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol (2008) 4.24
Gastric adenocarcinoma: review and considerations for future directions. Ann Surg (2005) 3.83
Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol (2011) 3.75
Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol (2007) 3.58
Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes. J Clin Oncol (2003) 3.56
Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology (2008) 3.28
Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res (2009) 3.06
Randomized controlled trial of the effects of print materials and step pedometers on physical activity and quality of life in breast cancer survivors. J Clin Oncol (2007) 2.65
Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol (2007) 2.53
Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol (2002) 2.23
The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res (2004) 2.06
Effects of an oncologist's recommendation to exercise on self-reported exercise behavior in newly diagnosed breast cancer survivors: a single-blind, randomized controlled trial. Ann Behav Med (2004) 2.04
Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol (2008) 1.99
Effects of exercise training on fasting insulin, insulin resistance, insulin-like growth factors, and insulin-like growth factor binding proteins in postmenopausal breast cancer survivors: a randomized controlled trial. Cancer Epidemiol Biomarkers Prev (2003) 1.89
A multicenter study of the revised Edmonton Staging System for classifying cancer pain in advanced cancer patients. J Pain Symptom Manage (2005) 1.86
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol (2008) 1.76
Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer (2006) 1.75
Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. Lancet Oncol (2009) 1.75
Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol (2010) 1.74
Possible links between behavioral and physiological indices of tiredness, fatigue, and exhaustion in advanced cancer. Support Care Cancer (2007) 1.68
Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology (2012) 1.67
DEAD box 1: a novel and independent prognostic marker for early recurrence in breast cancer. Breast Cancer Res Treat (2010) 1.65
The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer (2007) 1.63
Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res (2009) 1.62
Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum. J Clin Oncol (2012) 1.61
Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am J Gastroenterol (2002) 1.60
Effect of capecitabine on mean corpuscular volume in patients with metastatic breast cancer. Am J Clin Oncol (2004) 1.60
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol (2011) 1.59
An international multicentre validation study of a pain classification system for cancer patients. Eur J Cancer (2010) 1.59
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res (2011) 1.56
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst (2013) 1.54
Can quantifying hormone receptor levels guide the choice of adjuvant endocrine therapy for breast cancer? J Clin Oncol (2011) 1.48
Effect of exercise training on C-reactive protein in postmenopausal breast cancer survivors: a randomized controlled trial. Brain Behav Immun (2005) 1.45
Effects of presurgical exercise training on cardiorespiratory fitness among patients undergoing thoracic surgery for malignant lung lesions. Cancer (2007) 1.41
Dosimetric consequences of increased seed strength for I-125 prostate implants. Radiother Oncol (2003) 1.39
Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis. J Clin Oncol (2008) 1.33
Prospective cohort study of lifetime physical activity and breast cancer survival. Int J Cancer (2009) 1.32
Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms. Circulation (2011) 1.30
Randomized controlled trial of exercise and blood immune function in postmenopausal breast cancer survivors. J Appl Physiol (1985) (2005) 1.29
Clinical trial of post-chemotherapy consolidation thoracic radiotherapy for extensive-stage small cell lung cancer. Radiother Oncol (2011) 1.28
Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer. Int J Radiat Oncol Biol Phys (2004) 1.24
Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin Cancer Res (2006) 1.24
Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. BMC Pharmacol (2004) 1.23
Predictors of supervised exercise adherence during breast cancer chemotherapy. Med Sci Sports Exerc (2008) 1.23
The addition of manual lymph drainage to compression therapy for breast cancer related lymphedema: a randomized controlled trial. Breast Cancer Res Treat (2004) 1.22
Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer. Cancer Res (2009) 1.21
What procedures are students doing during undergraduate surgical clerkship? Can J Surg (2006) 1.21
Senescence evasion by MCF-7 human breast tumor-initiating cells. Breast Cancer Res (2010) 1.19
Safety and feasibility of cardiopulmonary exercise testing in patients with advanced cancer. Lung Cancer (2006) 1.19
Effects of exercise dose and type during breast cancer chemotherapy: multicenter randomized trial. J Natl Cancer Inst (2013) 1.18
Physical exercise and immune system function in cancer survivors: a comprehensive review and future directions. Cancer (2002) 1.18
Exercise for breast cancer survivors: research evidence and clinical guidelines. Phys Sportsmed (2002) 1.16
Barriers to supervised exercise training in a randomized controlled trial of breast cancer patients receiving chemotherapy. Ann Behav Med (2008) 1.16
Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab. Cancer Epidemiol Biomarkers Prev (2007) 1.16
Moderators of the effects of exercise training in breast cancer patients receiving chemotherapy: a randomized controlled trial. Cancer (2008) 1.15
Analyzing theoretical mechanisms of physical activity behavior change in breast cancer survivors: results from the activity promotion (ACTION) trial. Ann Behav Med (2008) 1.15
Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation (2012) 1.14
Predictors of follow-up exercise behavior 6 months after a randomized trial of exercise training during breast cancer chemotherapy. Breast Cancer Res Treat (2008) 1.10
Effects of exercise training on antitumor efficacy of doxorubicin in MDA-MB-231 breast cancer xenografts. Clin Cancer Res (2005) 1.09
cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. Lung Cancer (2005) 1.09
In the end what matters most? A review of clinical endpoints in advanced breast cancer. Oncologist (2011) 1.09
Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. Cancer (2010) 1.09
Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemother Pharmacol (2006) 1.09
Correlation between saliva production and quality of life measurements in head and neck cancer patients treated with intensity-modulated radiotherapy. Am J Clin Oncol (2007) 1.09
Is pain intensity a predictor of the complexity of cancer pain management? J Clin Oncol (2008) 1.08
Potential novel candidate polymorphisms identified in genome-wide association study for breast cancer susceptibility. Hum Genet (2011) 1.08
An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol (2010) 1.08
Six-month follow-up of patient-rated outcomes in a randomized controlled trial of exercise training during breast cancer chemotherapy. Cancer Epidemiol Biomarkers Prev (2007) 1.07
Attitudes of terminally ill cancer patients about euthanasia and assisted suicide: predominance of psychosocial determinants and beliefs over symptom distress and subsequent survival. J Clin Oncol (2002) 1.05
Adjuvant trastuzumab induces ventricular remodeling despite aerobic exercise training. Clin Cancer Res (2009) 1.04
Oncologists' opinions towards recommending exercise to patients with cancer: a Canadian national survey. Support Care Cancer (2005) 1.03
Association of FABP5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapy. Am J Pathol (2011) 1.03
Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer. J Cell Physiol (2010) 1.02
Conservative and dietary interventions for cancer-related lymphedema: a systematic review and meta-analysis. Cancer (2010) 1.02
Cardiovascular reserve and risk profile of postmenopausal women after chemoendocrine therapy for hormone receptor--positive operable breast cancer. Oncologist (2007) 1.01
Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells. Cell Signal (2007) 1.00
Long-term outcomes of submandibular gland transfer for prevention of postradiation xerostomia. Arch Otolaryngol Head Neck Surg (2004) 1.00
Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine. Br J Haematol (2003) 1.00
Health-related quality of life measures in routine clinical care: can FACT-fatigue help to assess the management of fatigue in cancer patients? Int J Technol Assess Health Care (2009) 1.00
Environmental, genetic, and molecular features of prostate cancer. Lancet Oncol (2004) 0.99
Effects of exercise during adjuvant chemotherapy on breast cancer outcomes. Med Sci Sports Exerc (2014) 0.99
Exercise issues in older cancer survivors. Crit Rev Oncol Hematol (2004) 0.99
The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer. Breast Cancer Res Treat (2010) 0.99
Signal transducers and activators of transcription-3 up-regulates tissue inhibitor of metalloproteinase-1 expression and decreases invasiveness of breast cancer. Am J Pathol (2006) 0.99
MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib. Neuro Oncol (2010) 0.99
The role of membrane transporters in cellular resistance to anticancer nucleoside drugs. Cancer Treat Res (2002) 0.99
Microglandular adenosis with transition into adenoid cystic carcinoma of the breast. Am J Surg Pathol (2003) 0.98